Furthermore, low dose of PTL (10 μM) used does not dramatically affects the human hepatocyte LO2 cells and HCC cell lines, instead, enhances the efficacy of ATO, indicating that PTL may be a more advantageous agent combined with ATO than other chemotherapeutics in treatment of HCC. This evidence concerns the gene PNLIP and hepatocellular carcinoma.